Arcutis (NASDAQ: ARQT) director awarded RSUs and 16,667-share stock option

Rhea-AI Filing Summary

Arcutis Biotherapeutics director Howard G. Welgus received new equity awards as part of his board compensation. He acquired 5,778 Restricted Stock Units, each convertible into one share of common stock upon vesting, and a stock option for 16,667 shares at an exercise price of $21.23 per share.

The RSUs and option both vest 100% on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting of stockholders, subject to continued service. Following the RSU grant, he directly holds 38,378 shares of common stock.

Insights

Equity compensation analyst

Director received routine RSU and stock option grants as board compensation.

The filing shows Howard G. Welgus, a non-employee director of Arcutis Biotherapeutics, receiving equity awards instead of cash-only pay. He was granted 5,778 RSUs and an option over 16,667 shares at $21.23 per share, both dated June 5, 2026.

These awards vest fully on the earlier of the first anniversary of the grant or immediately before the next annual stockholder meeting, contingent on continued service. After the RSU grant, Welgus directly holds 38,378 common shares, indicating this is a modest, compensation-related award rather than a large directional trade.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Welgus Howard G.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	16,667	$0.00	--
Grant/Award	Common Stock	5,778	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 16,667 shares (Direct, null); Common Stock — 38,378 shares (Direct, null)

Footnotes (1)

1. Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

Key Figures

RSU grant: 5,778 units Stock option grant: 16,667 shares Option exercise price: $21.23 per share +2 more

5 metrics

RSU grant 5,778 units Restricted Stock Units granted June 5, 2026 for director service

Stock option grant 16,667 shares Option over common stock granted June 5, 2026

Option exercise price $21.23 per share Exercise price for 16,667-share stock option

Shares held after RSU grant 38,378 shares Total common shares directly held following RSU award

Option expiration June 5, 2036 Expiration date of stock option grant

Key Terms

Restricted Stock Units ("RSUs"), Stock Option (right to buy), non-employee director, annual meeting of stockholders

4 terms

Restricted Stock Units ("RSUs") financial

"Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise price of 21.2300"

non-employee director financial

"granted in connection with the Reporting Person's service as a non-employee director"

annual meeting of stockholders financial

"on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Welgus Howard G.

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CALIFORNIA 91361

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		5,778(1)	A	$0	38,378	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$21.23	06/05/2026		A		16,667		(2)	06/05/2036	Common Stock	16,667	$0	16,667	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

2. The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

Remarks:

	/s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Arcutis Biotherapeutics (ARQT) director Howard G. Welgus receive?

Howard G. Welgus received 5,778 Restricted Stock Units and a stock option for 16,667 shares at an exercise price of $21.23 per share. These awards were granted as compensation for his service as a non-employee director.

When do Howard G. Welgus’s new RSUs from Arcutis (ARQT) vest?

The 5,778 RSUs vest 100% on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting of stockholders, provided Welgus continues serving as a director through the vesting date.

What are the terms of Howard G. Welgus’s new stock option in Arcutis (ARQT)?

Welgus received an option covering 16,667 shares of Arcutis common stock at an exercise price of $21.23 per share. The option vests entirely on the earlier of June 5, 2026, or immediately before the next annual meeting, subject to continued board service.

How many Arcutis (ARQT) shares does Howard G. Welgus hold after this Form 4?

Following the RSU grant reported, Howard G. Welgus directly holds 38,378 shares of Arcutis common stock. This figure reflects his position after the June 5, 2026 award of 5,778 RSUs tied to his non-employee director service.

Are Howard G. Welgus’s Arcutis (ARQT) equity grants open-market purchases or compensation awards?

The reported transactions are compensation-related awards, not open-market purchases. They include a grant of RSUs and a stock option awarded for his service as a non-employee director, both carrying a transaction code A for grant or award acquisition.